Brentuximab vedotin plus CHP-like versus CHOEP regimen for the first-line treatment of PTCL patients: a multi-center propensity-matched retrospective study
- 1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- 2Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University
- 3Department of Hematology, Yichang National Regional Medical Center
Abstract
Introduction: The optimal frontline treatment option for Peripheral T-cell lymphomas (PTCLs) has not been completely defined.
Methods: To compare the efficacy and safety of brentuximab vedotin (BV) combined with CHP-like regimen (cyclophosphamide, an anthracycline component, and prednisone) and CHOEP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone and etoposide) as first-line treatment for newly diagnosed PTCLs, we used 1:1 optimal propensity score-matching (PSM) to match patients by gender, age, disease stage, bone marrow infiltration, extranodal involvement, Eastern Cooperative Oncology Group performance status, and PTCL subtype, resulting in two cohorts of 45 patients each.
Results: With a median follow-up of 27.2 months, the 2-year progression-free survival (PFS) rates were 70.7% (95% confidence interval [CI]: 58.5%-85.5%) and 45.3% (95% CI: 32.7%-62.7%) for the BV plus CHP-like and CHOEP groups, respectively (P = 0.012). The 2-year overall survival (OS) rate was 81.0% (95% CI: 68.8%-95.3%) in the BV plus CHP-like group and 75.1% (95% CI: 62.7%-90.1%) in the CHOEP group (P = 0.550). No significant differences were observed between the two groups in complete remission (CR, P = 0.673) and objective response rate (ORR, P = 0.662) at the end-of-follow-up assessment. The duration of response (DOR) in the BV plus CHP-like group was significantly prolonged compared to the CHOEP group (81.9% vs. 63.0%, P = 0.035). In subgroup analysis stratified by ALK expression, no deaths occurred among the 31 ALK-positive ALCL patients; the 2-year PFS rate was 94.4% versus 76.9% (P = 0.066). Among the 59 non-ALK-positive PTCL patients, no significant differences were observed in OS (P = 0.880) or PFS (P = 0.110). BV plus CHP-like regimen was associated with a lower incidence of hematological toxicities than the CHOEP regimen, both for any-grade and for grade ≥ 3 events.
Conclusion: The BV plus CHP-like regimen may improve the PFS, without increasing hematological adverse events. However, this benefit was largely offset in non-ALK-positive PTCL patients, and further validation in larger cohorts is warranted.
Related
- Efficacy and safety of sintilimab plus bevacizumab with or without transarterial chemoembolization for unresectable hepatocellular carcinoma: a propensity score-matched retrospective cohort study
- Neoadjuvant disitamab vedotin (RC-48) plus a PD-1 inhibitor in muscle-invasive bladder cancer: a multicenter real-world study with stratification by HER2 expression and tertiary lymphoid structures
- Enhanced enfortumab vedotin sensitivity in a cisplatin-resistant bladder cancer model
- Clinical characteristics and early hematoma dynamics in a selected cohort of 199 patients with spontaneous intracerebral hemorrhage who underwent 24-hour follow-up imaging: a retrospective single-center study
- Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma
BibTeX
@article{chen2026brentuximab,
title = {{Brentuximab vedotin plus CHP-like versus CHOEP regimen for the first-line treatment of PTCL patients: a multi-center propensity-matched retrospective study}},
author = {Jing Chen and Fangshu Guan and Zhipeng Cheng and Yingying Wu and Lin Liu and Lu Zhang and Fang Liu and Guohui Cui and Heng Mei and Fanjun Cheng and Yi Zhao and Jun Fang},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1973646},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1973646/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Brentuximab vedotin plus CHP-like versus CHOEP regimen for the first-line treatment of PTCL patients: a multi-center propensity-matched retrospective study
AU - Jing Chen
AU - Fangshu Guan
AU - Zhipeng Cheng
AU - Yingying Wu
AU - Lin Liu
AU - Lu Zhang
AU - Fang Liu
AU - Guohui Cui
AU - Heng Mei
AU - Fanjun Cheng
AU - Yi Zhao
AU - Jun Fang
PY - 2026
DA - 2026/10/21
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1973646
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1973646/full
AB - Introduction: The optimal frontline treatment option for Peripheral T-cell lymphomas (PTCLs) has not been completely defined. Methods: To compare the efficacy and safety of brentuximab vedotin (BV) combined with CHP-like regimen (cyclophosphamide, an anthracycline component, and prednisone) and CHOEP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone and etoposide) as first-line treatment for newly diagnosed PTCLs, we used 1:1 optimal propensity score-matching (PSM) to match patients by gender, age, disease stage, bone marrow infiltration, extranodal involvement, Eastern Cooperative Oncology Group performance status, and PTCL subtype, resulting in two cohorts of 45 patients each. Results: With a median follow-up of 27.2 months, the 2-year progression-free survival (PFS) rates were 70.7% (95% confidence interval [CI]: 58.5%-85.5%) and 45.3% (95% CI: 32.7%-62.7%) for the BV plus CHP-like and CHOEP groups, respectively (P = 0.012). The 2-year overall survival (OS) rate was 81.0% (95% CI: 68.8%-95.3%) in the BV plus CHP-like group and 75.1% (95% CI: 62.7%-90.1%) in the CHOEP group (P = 0.550). No significant differences were observed between the two groups in complete remission (CR, P = 0.673) and objective response rate (ORR, P = 0.662) at the end-of-follow-up assessment. The duration of response (DOR) in the BV plus CHP-like group was significantly prolonged compared to the CHOEP group (81.9% vs. 63.0%, P = 0.035). In subgroup analysis stratified by ALK expression, no deaths occurred among the 31 ALK-positive ALCL patients; the 2-year PFS rate was 94.4% versus 76.9% (P = 0.066). Among the 59 non-ALK-positive PTCL patients, no significant differences were observed in OS (P = 0.880) or PFS (P = 0.110). BV plus CHP-like regimen was associated with a lower incidence of hematological toxicities than the CHOEP regimen, both for any-grade and for grade ≥ 3 events. Conclusion: The BV plus CHP-like regimen may improve the PFS, without increasing hematological adverse events. However, this benefit was largely offset in non-ALK-positive PTCL patients, and further validation in larger cohorts is warranted.
SN - 1664-3224
ER -